CelLBxHealth plc ANPCY
0.07 USD 0.00 (+0.00%)
At closeJan 2, 2026, 4:00 PM EST
0.067 Day range 0.068
0.0666 52-week range 2.39
- YTD
- 0.00%
- 1 year
- -95.04%
News
prnewswire.com T. ROWE PRICE LAUNCHES SEASON 6 OF "THE ANGLE" PODCAST SERIES WITH INVESTOR-FOCUSED LOOK AT AI ADOPTION New season, "AI at Work: From Promise to Impact," examines where artificial intelligence may create lasting value, where expectations may be too high, and what investors should watch as adoption…
proactiveinvestors.co.uk CelLBxHealth shares rise 8% on Royal Marsden lung cancer collaboration CelLBxHealth PLC (AIM:CLBX, FRA:DWV) shares rose 8% to 0.99p after the AIM-listed circulating tumour cell specialist announced a research collaboration with The Royal Marsden NHS Foundation Trust to…
proactiveinvestors.co.uk CelLBxHealth joins forces with The Royal Marsden on lung cancer liquid biopsy study CelLBxHealth PLC (AIM:CLBX, FRA:DWV), a specialist in circulating tumour cell (CTC) analysis, has announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel…
proactiveinvestors.co.uk CelLBxHealth shares rise 3% as company continues to focus on cost base Shares in CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) rose 3% to 1.08p on Thursday after the company announced it would discontinue its United States Food and Drug Administration establishment…
proactiveinvestors.co.uk CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) has decided to discontinue maintenance of its United States Food and Drug Administration establishment licence and device listing for the Parsortix…
proactiveinvestors.co.uk CelLBxHealth backed for rebound by broker CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) is a recovery story with asymmetric upside. In a note published on Friday, Cavendish reiterated its 4.0p price target, implying more than 300% upside…
proactiveinvestors.co.uk CelLBxHealth enters 2026 with strong pipeline CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) said it is entering 2026 with a sharpened strategy and a focus on turning a £12.6 million sales pipeline into revenues, adding that its balance sheet…
proactiveinvestors.co.uk CelLBxHealth Health confirms boardroom appointments CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF) has confirmed board appointments signed off at a board meeting last month, with its chief executive and three non-executive directors formally taking up their…
prnewswire.com T. ROWE PRICE LAUNCHES SEASON 5 OF "THE ANGLE" PODCAST SERIES WITH EXPLORATION OF THE GLOBAL ENERGY SECTOR T. Rowe Price equity portfolio specialist Jackie Fortner hosts a deep dive featuring company energy experts in oil and gas, utilities, and sustainability BALTIMORE, Jan. 8, 2026 /PRNewswire/ -- T.…
defenseworld.net ANGLE plc (OTCMKTS:ANPCY) Short Interest Down 94.5% in December ANGLE plc (OTCMKTS:ANPCY - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 2,799…
proactiveinvestors.co.uk CellbxHealth raises just shy of £1m in retail offer CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF) has wrapped up its latest retail fundraise, bringing in about £960,000 as part of a wider financing package designed to support the diagnostics company's…
seekingalpha.com CelLBxHealth plc (ANPCY) Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation Transcript CelLBxHealth plc (ANPCY) Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation Transcript
proactiveinvestors.co.uk CelLBxHealth plans £6.8 million fundraise as it pushes for commercial reboot CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF), the cancer diagnostics group formerly known as Angle, has outlined plans to raise £6.8 million as it tries to stabilise its finances and accelerate a shift…
accessnewswire.com CelLBxHealth PLC Presents Proof-of-Concept Study CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development conference Parsortix platform shown to be compatible with the Roche BenchMark…
proactiveinvestors.co.uk CelLBxHealth backed by expert panel as Parsortix named top cancer technology and plans £6m fundraise CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) received a strong endorsement from leading cancer specialists for its Parsortix platform, as it confirmed it is preparing to raise around £6 million to support…
accessnewswire.com Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation Technology Expert consensus predicts integration of CTC testing into…
proactiveinvestors.co.uk ANGLE appoints interim CEO ahead of name change and restructure ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the UK-based cancer diagnostics firm soon to be renamed CelLBxHealth, has appointed Peter Collins as interim chief executive and brought on Klaas de Boer as a senior…
accessnewswire.com ANGLE plc Announces Appointments: Interim CEO and Senior Board Advisor GUILFORD, SURREY / ACCESS Newswire / October 16, 2025 / ANGLE plc (to be renamed CelLBxHealth plc) (AIM:AGL)(OTCQX:ANPCY), a world-leading circulating tumour cell (CTC) intelligence company with…
proactiveinvestors.co.uk ANGLE to rebrand as CelLBxHealth and shift focus under new executive chairman ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the cancer diagnostics group behind the Parsortix blood testing platform, is changing its name to CelLBxHealth and adopting a tighter commercial focus as it seeks to…
accessnewswire.com Angle PLC Announces Strategy Update Appointment of Executive Chairman, proposed change of name and strategy update Company to pursue revised strategy and name change to CelLBxHealth plc Dr. Jan Groen, the current Non-Executive Chairman…